Evolva receives grant from US CDC in the amount of USD 540,000
businessinsider.com
finance
2022-10-21 07:00:30

Reinach, 21 October 2022 Evolva (SIX:EVE) a pioneer in the field of natural molecules and industrial biotech, has received a grant of USD 540,000 from the US Centers for Disease Control and Prevention (CDC) for the development of NootkaSHIELDTM Â for new formulations and applications in the area of tick bite prevention. The grant will be distributed in several payments over a period of 18 months, commencing on 30 September 2022. The grant is an important milestone in bringing NootkaSHIELDTM, a next-generation protection against vector-borne deseases spread by insects and ticks, to the US market.
